Methods Between April and May 2010, CD4+ test results were collected for all HIV-infected patients recorded in the pre-ART and ART registers of 19 high-patient-load health centres in Addis Ababa, Ethiopia, and the regions of Amhara, Oromia, SNNPR (Southern Nations, Nationalities and People's Region) and Tigray. At 12 centres patient records were independently reviewed to assess data accuracy. To estimate the total number of patients who would need ART at health centres if Ethiopia adopted the new WHO guidelines, the number of patients needing ART based on current guidelines were added to the number of asymptomatic patients enrolled in pre-ART with a CD4+ count > 200 but ≤ 350 cells/mm 3 Findings Adoption of the new WHO guidelines would increase the total number of patients on ART in the 19 health centres in Ethiopia by about 30%: from 3583 to 4640.
In 2010, the World Health Organization (WHO) issued new guidelines for the initiation of antiretroviral therapy (ART) in adults and adolescents with human immunodeficiency virus (HIV) infection. The guidelines cover a range of issues associated with ART, including initiation of the regimen at an earlier stage of infection, updated first-and second-line drug regimens and improved criteria for switching antiretrovirals. 1 This paper focuses on the CD4+ Tlymphocyte (CD4+) count used as the clinical threshold for initiating ART, which has been shifted to ≤ 350 cells/mm3 from the former standard, ≤ 200 cells /mm 3 .
Studies and modelling exercises suggest that HIV-related mortality could be reduced by 20% between 2010 and 2015 by raising the CD4+ cell threshold required for initiating ART.
Another possible benefit would be reduced HIV transmission between couples and from mother to child. An increase in the CD4+ threshold and hence in the demand for treatment entails certain risks, however: a rise in treatment costs as high as 57%; the displacement of patients in urgent need of ART; longer exposure to ART, resulting in unknown side-effects and in the development of resistance mechanisms. WHO has declared that in making these revisions, a high value, over and above cost and feasibility, was placed on avoiding death, disease progression and HIV transmission. 1 However, implementing these guidelines is not always possible in the countries where ART is most needed.
Some studies on the feasibility of implementing WHO guidelines in resource-constrained settings have been conducted, and many of them have shown that in such settings health system constraints make it difficult to roll out the new WHO guidelines. 2, 3 According to one modelbased analysis that projected clinical and economic outcomes in a South African HIV-infected cohort, initiation of ART in patients with a CD4+ count of ≤ 350 cells/mm 3 provides the greatest short-and long-term survival advantage and is also highly cost-effective. 2 Other studies that have explored how health system constraints impeded the roll-out of the 2006 WHO guidelines count among the barriers ART stock-outs, lack of capability for performing CD4+ counts and human resource shortages. The same factors are obviously applicable to the new 2010 guidelines. 4, 5 If countries are to adopt the new WHO guidelines, the health system will have to be equipped to conduct more HIV tests and CD4+ counts and health-care services will have to become capable of absorbing higher patient case-loads. A study using Cameroon, Kenya, initiating ART would increase the number of patients requiring ART not only in the immediate future, but also in the long term. 4 
Context in Ethiopia
While the overall prevalence of HIV infection in Ethiopia, which is currently 2.1%, remains relatively low, the country is home to an estimated 1.1 million HIV-positive people. 6 In response to the HIV/AIDS epidemic, the Government of Ethiopia made drastic policy shifts that set a precedent in sub-Saharan Africa. Comprehensive HIV/AIDS services, including ART, were made widely available free of charge to the country's population of nearly 80 million people. To ensure the availability of these services, the government decentralized HIV patient care, which it transferred from physicians in hospitals to mid-level health-care workers in health centres. Nurses and health officers in health centres are also supported by the work of community health workers administering community-based and home-based care.
Unlike its neighbouring countries, Ethiopia has a good supply of ART drugs. The unmet need for ART in Ethiopia is caused not by a shortage of drugs, but by health system constraints.
Many health centres do not have the equipment for conducting CD4+ counts and yet lack a vehicle for transporting samples quickly and safely to the nearest hospital having the required machine. Furthermore, hospitals are putting caps on the number of health centre samples processed. The health system also lacks mechanisms for tracking pre-ART patients. Plans are under way to introduce pre-ART registers and develop a routine appointment system to prevent losses to follow-up among these patients. Because of all of these constraints, in Ethiopia some would correspond to a 30% increase in the total load of patients on ART.
A subset of patient records at the 12 most accessible health centres were independently verified one month after data collection. At four such health centres, 298 records were verified for staging. Of these, 8 (2.7%) records showed data errors. Data on patients with a CD4+ count of < 50 cells/mm 3 were verified for all patients at eight health centres and for a random sample of 58 of 247 patients (24%) at the other four health centres. Of these patient records, 4.6% contained patient CD4+ counts that differed by more than 5% from the reported Counts. If, for instance, the reported CD4+ count was 300 cells/mm 3 and the recorded count was 400 cells/mm 3 , the difference between the two was 25%, a value above the 5% difference considered acceptable.
Data on CD4+ counts ranging from 50 to 900 cells/mm 3 were verified for 88 of 425 (21%) patients at one health centre; 2.3% of these records were found to contain CD4+ counts that deviated by more than 5% from the original data. Lastly, CD4+ counts > 900 cells/mm 3 were verified for all patients at eight health centres and for 21 of 24 patients (88%) at the four additional health centres. The proportion of records showing a difference in CD4+ data of more than 5% was 3.1%. Overall, 5.3% of patient records were verified for data accuracy and 3.8% of these records deviated by more than 5% from the data collected originally. This shift in the CD4+ threshold for ART initiation will only increase the demand for ART. With the systems currently in place, only 60% of eligible patients are receiving ART.
Without concurrent increases in funding and governmental support, it will not be possible to scale up ART programmes to accommodate the increased patient demand in Ethiopia. These increased costs are not currently affordable for the Ethiopian Government, which has decided to continue to observe the 2006 ART guidelines. While the 2010 revision is sound in principle and value, resources in Ethiopia are not enough to absorb the ensuing increased demand for existing services.
Other resource-poor countries that have elected to implement the new WHO guidelines may face similar challenges and could benefit from an effort to estimate how much the change in policy would increase the load of patients needing ART. The results may prove useful for resource analysis and planning and for determining the feasibility of adopting the new WHO guidelines on ART initiation and the country's readiness to do so.
